• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Indivior PLC

    6/21/24 6:04:48 PM ET
    $INDV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDV alert in real time by email
    SC 13D/A 1 form_sc13da-indivior.htm

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     _____________________________________
     
    SCHEDULE 13D
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*
     
     _____________________________________
    INDIVIOR PLC
    (Name of Issuer)
    Ordinary Shares, $0.50 nominal value per share
    (Title and Class of Securities)
    G4766E116
    (CUSIP Number)
    Lawrence V. Palermo
    Two Seas Capital LP
    32 Elm Place, 3rd Floor
    Rye, NY 10580
    (646) 420-4504
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    June 20, 2024
    (Date of Event Which Requires Filing of Statement)
     
    _____________________________________
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box.  [  ]

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.
     
    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)
     

    Schedule 13D
     CUSIP No. G4766E116
     
     
     
                 
      (1) 
     
    Name of Reporting Persons:
     
    Two Seas Capital LP
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Source of Funds (See Instructions):
     
    AF
      (5)
     
    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  ☐
     
      (6)
     
    Citizenship or Place of Organization:
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (7) 
      
    Sole Voting Power
     
    13,260,025
      
      (8)
      
    Shared Voting Power
     
    0
      
      (9)
      
    Sole Dispositive Power
     
    13,260,025
      
    (10)
      
    Shared Dispositive Power
     
    0
    (11)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    13,260,025
    (12)
     
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):  ☐
     
    (13)
     
    Percent of Class Represented by Amount in Row (11):
     
    9.9% (1)
    (14)
     
    Type of Reporting Person (See Instructions):
     
    PN, IA
     
    (1)
     Based on 134,125,403 Ordinary Shares of Indivior PLC (the “Issuer”) outstanding as of June 20, 2024, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (“SEC”) on June 21, 2024.



    Schedule 13D
    CUSIP No. G4766E116
     
     

                 
      (1) 
     
    Name of Reporting Persons:
     
    Two Seas Capital GP LLC
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Source of Funds (See Instructions):
     
    AF
      (5)
     
    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  ☐
     
      (6)
     
    Citizenship or Place of Organization:
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (7) 
      
    Sole Voting Power
     
    13,260,025
      
      (8)
      
    Shared Voting Power
     
    0
      
      (9)
      
    Sole Dispositive Power
     
    13,260,025
      
    (10)
      
    Shared Dispositive Power
     
    0
    (11)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    13,260,025
    (12)
     
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):  ☐
     
    (13)
     
    Percent of Class Represented by Amount in Row (11):
     
    9.9% (1)
    (14)
     
    Type of Reporting Person (See Instructions):
     
    OO, HC
     
    (1)
     Based on 134,125,403 Ordinary Shares of the Issuer outstanding as of June 20, 2024, as reported in the Issuer’s Form 6-K filed with the SEC on June 21, 2024.


    Schedule 13D
     
    CUSIP No. G4766E116
     
     
     
                 
      (1) 
     
    Name of Reporting Persons:
     
    Sina Toussi
      (2)
     
    Check the Appropriate Box if a Member of a Group (See Instructions):
    (a)  ☐        (b)  ☐
     
      (3)
     
    SEC Use Only:
     
      (4)
     
    Source of Funds (See Instructions):
     
    AF
      (5)
     
    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):  ☐
     
      (6)
     
    Citizenship or Place of Organization:
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
     
      
      (7) 
      
    Sole Voting Power
     
    13,260,025
      
      (8)
      
    Shared Voting Power
     
    0
      
      (9)
      
    Sole Dispositive Power
     
    13,260,025
      
    (10)
      
    Shared Dispositive Power
     
    0
    (11)
     
    Aggregate Amount Beneficially Owned by Each Reporting Person:
     
    13,260,025
    (12)
     
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):  ☐
     
    (13)
     
    Percent of Class Represented by Amount in Row (11):
     
    9.9% (1)
    (14)
     
    Type of Reporting Person (See Instructions):
     
    HC, IN
     
    (1)
    Based on 134,125,403 Ordinary Shares of the Issuer outstanding as of June 20, 2024, as reported in the Issuer’s Form 6-K filed with the SEC on June 21, 2024.


    AMENDMENT NO. 2 TO SCHEDULE 13D

    The following constitutes Amendment No. 2 (“Amendment No. 2”) to the Schedule 13D filed with the Securities and Exchange Commission (“SEC”) by Two Seas Capital LP (“TSC”), Two Seas Capital GP LLC (“TSC GP”) and Sina Toussi on October 2, 2023, as amended by Amendment No. filed on March 29, 2024.  This Amendment No. 2 amends and supplements the Schedule 13D as specifically set forth herein.

    All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.
     
    ITEM 3.
    SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

    Item 3 of the Schedule 13D is hereby amended and restated as follows:

    The aggregate purchase price of the 12,089,278 Ordinary Shares directly held by the Litigation Fund reported herein was approximately $111,662,690. The aggregate purchase price of the 1,170,747 Ordinary Shares directly held by the Global Fund reported herein was approximately $16,303,642. The Ordinary Shares directly held by the Funds were purchased with the working capital of the Funds (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) and proceeds from the Credit Facility (the “Credit Facility”) for the Litigation Fund, provided by UBS AG, London Branch (“UBS”), pursuant to the Credit Facility Agreement, by and between, the Litigation Fund, as Borrower, and UBS, acting as Lender, dated June 16, 2022, as amended and restated on September 22, 2022, on April 5, 2023, and on June 19, 2023, as amended on December 20, 2023, and as amended and restated by the Fifth Amendment Agreement, dated June 20, 2024 (the “Credit Facility Agreement”). All Ordinary Shares reported herein were purchased in open market transactions through a broker other than 5,200,000 Ordinary Shares purchased by the Litigation Fund and 300,000 Ordinary Shares purchased by the Global Fund in a private transaction with a third party investor on June 16, 2022.

    ITEM 5.
    INTEREST IN SECURITIES OF THE ISSUER

    Item 5 of the Schedule 13D is hereby amended and restated as follows:

    (a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference. Such information is based on 134,125,403 Ordinary Shares of the Issuer outstanding as of June 20, 2024, as reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission on June 21, 2024. The information in Item 3 regarding the number of Ordinary Shares held by the Funds is incorporated herein by reference.

    The Funds have delegated to TSC sole voting and investment power over the securities held by the Funds pursuant to their respective Investment Management Agreements with TSC. As a result, each of TSC, TSC GP, as the general partner of TSC, and Mr. Toussi, as Chief Investment Officer of TSC and Managing Member of TSC GP, may be deemed to exercise voting and investment power over the Ordinary Shares directly held by the Funds. The Funds specifically disclaim beneficial ownership of the securities of the Issuer directly held by them by virtue of their inability to vote or dispose of such securities as a result of their respective Investment Management Agreements with TSC.

    (c) Transactions by the Reporting Persons (on behalf of the Funds) effected during the past 60 days are set forth in Schedule A below and such information is incorporated herein by reference.

    (d) The disclosure regarding the relationship between the Reporting Persons in Item 2(c) of this Schedule 13D is incorporated herein by reference. All securities reported in this Schedule 13D are directly held by the Funds, each of which are investment management clients of TSC. The limited partners of (or investors in) each of the Funds have the right to participate in the receipt of dividends from, or proceeds from the sale of, the Ordinary Shares held for the accounts of their respective Funds in accordance with their respective limited partnership interests (or investment percentages) in their respective Funds.

    (e) Not applicable.

    ITEM 6.
    CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER

    Item 6 of this Schedule 13D is supplemented and superseded, as the case may be, as follows:

    Pursuant to the Security Agreement, dated June 16, 2022, by and between the Litigation Fund, as Grantor, and UBS, as Secured Party, as amended (the “Security Agreement”), the Litigation Fund has pledged to UBS 10,899,480 Ordinary Shares held by it. If the Litigation Fund defaults on its obligations under the Credit Facility Agreement, such default could result in foreclosure proceedings against the Ordinary Shares pledged as collateral by the Litigation Fund, subject to a beneficial ownership limitation.  The pledged Ordinary Shares are subject to certain transfer restrictions.  The total commitment under the Credit Facility is $45,000,000 and $42,609,098 is currently drawn. The Credit Facility is subject to typical credit terms and certain event of default triggers, some of which may be satisfied by unencumbered assets of the Litigation Fund. The maturity date for the Credit Facility is July 31, 2025, and the interest rate under the Credit Facility is a variable rate plus a reference rate.  The Global Fund has no potential encumbrances with respect to the Credit Facility.


    The Global Fund has entered into cash-settled swaps which represent economic exposure comparable to a notional interest in 1,509,081 Ordinary Shares (representing economic exposure comparable to approximately 1.1% of the outstanding Ordinary Shares) with Jefferies Financial Products, LLC and cash-settled swaps which represent economic exposure comparable to a notional interest in 311,421 Ordinary Shares (representing economic exposure comparable to approximately 0.2% of the outstanding Ordinary Shares) with Goldman Sachs International.  Under the terms of the swaps, (i) the Global Fund will be obligated to pay to the counterparty any negative price performance of the specified notional number of Ordinary Shares subject to the swaps as of the expiration date of such swaps, plus interest rates set forth in the applicable contracts, and (ii) the counterparty will be obligated to pay the Global Fund any positive price performance of the specified notional number of Ordinary Shares subject to the swaps as of the expiration date of the swaps.  All balances will be settled in cash. The swaps do not give the Reporting Persons or Funds direct or indirect voting, investment or dispositive control over any securities of the Issuer and do not require the counterparty thereto to acquire, hold, vote or dispose of any securities of the Issuer.  Accordingly, the Reporting Persons disclaim any beneficial ownership of any Ordinary Shares that may be referenced in the swap contracts or Ordinary Shares or other securities or financial instruments that may be held from time to time by any counterparty to the contracts.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
    Dated as of June 21, 2024
     
           
     
    TWO SEAS CAPITAL LP
         
     
    By:
     
    Two Seas Capital GP LLC, its general partner
         
     
    By:
     
    /s/ Sina Toussi
     
    Name:
     
    Sina Toussi
     
    Title:
     
    Managing Member
       
     
    TWO SEAS CAPITAL GP LLC
         
     
    By:
     
    /s/ Sina Toussi
     
    Name:
     
    Sina Toussi
     
    Title:
     
    Managing Member
     
     
    SINA TOUSSI
         
     
    By:
     
    /s/ Sina Toussi


    SCHEDULE A
    TRANSACTIONS
    The following table sets forth all transactions by the Reporting Persons (on behalf of the Funds) with respect to the Ordinary Shares effected in the last 60 days, inclusive of any transactions effected through 4:00 p.m., New York City time, on June 20, 2024. Except as otherwise noted below, all such transactions were purchases or sales of Ordinary Shares effected in the open market, and the table excludes commissions paid in per share prices.

    Amount Purchased/(Sold)
     
    Price Per
    Share (£) (or $ if noted below)
     
    Date of
    Purchase/Sale
    TWO SEAS GLOBAL (MASTER) FUND LP
     
             
     2,339
     
     15.051 (1)
     
    04/23/2024
    75,000
     
     14.0832 (2)
     
    04/25/2024
    2,765
     
     13.9772 (3)
     
    04/26/2024
    25,000
     
     14.2774 (4)
     
    05/01/2024
    30,000
     
     14.6419 (5)
     
    05/03/2024
    25,000
     
      14.3877 (6)
     
    05/10/3024
    7,781
     
      13.9955 (7)
     
    05/13/2024
    25,000
     
      14.0699 (8)
     
    05/15/2024
    25,000
     
       13.7035 (9)
     
    05/23/2024
    (100,000)
     
     14.25
     
    05/31/2024
    25,000
     
          13.1685 (10)
     
    06/06/2024
    (5,667)
     
           $15.9128 (11)
     
    06/18/2024
    (7,816)
     
          12.7901(12)
     
    06/19/2024
    (8,333)
     
     12.85
     
    06/20/2024
    (2,600)
     
           $16.1324 (13)
     
    06/20/2024
             
    TWO SEAS LITIGATION OPPORTUNITIES FUND LLC
     
             
     (34,982)
     
     12.7636 (14)
     
    06/18/2024
    (11,335)
     
    $15.9128 (15)
     
    06/18/2024
     (15,632)
     
     12.7901(16)
     
    06/19/2024
     (5,200)
     
    $16.1324 (17)
     
    06/20/2024
     (16,667)
     
    12.85
     
    06/20/2024
             
    (1) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £15.03 to £15.10, inclusive. The reporting persons undertake to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased or sold, as applicable, at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), and (17).
    (2) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £13.95 to £14.30, inclusive.
    (3) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £13.93 to £14.00, inclusive.
    (4) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £14.24 to £14.30, inclusive.
    (5) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £14.61 to £14.65, inclusive.
    (6) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £14.32 to £14.40, inclusive.
    (7) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £13.98 to £14.00, inclusive.
    (8) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £14.06 to £14.07, inclusive.
    (9) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £13.64 to £13.75, inclusive.
    (10) The purchase price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from £13.01 to £13.435, inclusive.
    (11) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.01, inclusive.

    (12) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from £12.65 to £12.88, inclusive.
    (13) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.16, inclusive.
    (14) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from £12.70 to £12.795, inclusive.
    (15) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.01, inclusive.
    (16) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from £12.65 to £12.88, inclusive.
    (17) The sale price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.16, inclusive.



    Get the next $INDV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INDV

    DatePrice TargetRatingAnalyst
    7/22/2025$20.00Buy
    Jefferies
    1/28/2025$16.00Buy
    Rodman & Renshaw
    7/23/2024$22.00Overweight
    Piper Sandler
    4/3/2024$37.00Buy
    Craig Hallum
    7/13/2023$35.00Outperform
    Northland Capital
    More analyst ratings

    $INDV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, United Kingdom and RICHMOND, Va., July 25, 2025 /PRNewswire/ -- Further to the announcement made on June 2, 2025, Indivior PLC (NASDAQ:INDV) today announces that: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List of the UK Financial Conduct Authority; and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's  main market for listed securities, have now been cancelled with effect from 08:00 a.m. UK time today, July 25, 2025 (the "London Delisting"). Indivior continues to maintain its primary listing of Ordinary Shares on the Nasdaq Stock Market.

      7/25/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

      Extended-release buprenorphine (BUP-XR) had lower rates of hospitalizations, emergency department (ED) visits, and outpatient physician office visits compared to those receiving daily oral buprenorphine or no medications for opioid use disorder (MOUD)The study indicates BUP-XR may be an important tool in reducing ED visits, improving healthcare resource utilization and patient outcomesRICHMOND, Va., July 23, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports, which examined demographic and clinical factors associated with ED visits among adults diagnosed with opioid use disorder

      7/23/25 8:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

      RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET.  Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event beg

      7/17/25 9:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies resumed coverage on Indivior with a new price target

      Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00

      7/22/25 7:52:44 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Indivior with a new price target

      Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00

      1/28/25 7:14:13 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Indivior with a new price target

      Piper Sandler initiated coverage of Indivior with a rating of Overweight and set a new price target of $22.00

      7/23/24 6:29:18 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    SEC Filings

    See more
    • Indivior PLC filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/30/25 7:03:38 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior PLC filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/24/25 4:52:40 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Indivior PLC

      8-K - INDIVIOR PLC (0001625297) (Filer)

      6/2/25 6:06:09 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Financials

    Live finance-specific insights

    See more
    • Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

      RICHMOND, Va., July 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U.S. ET.  Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. ET. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event beg

      7/17/25 9:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

      SLOUGH, England and RICHMOND, Va., June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting"). Background to and Reasons for the London Delisting In the circula

      6/2/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Q1 2025 Financial Results

      SLOUGH, United Kingdom and RICHMOND, Va., April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor presentation and webcast are available at www.indivior.com. The earnings release can be found at www.indivior.com/investorsThe investor presentation can be found at www.indivior.com/investors (at 7:00 am ET)There will be a live webcast presentation at 13:00 BST (8:00 am ET) hosted by Mark Crossley, CEO. The details are below. Webcast link: https://edge.media-server.com

      4/24/25 2:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Indivior PLC

      SC 13G - INDIVIOR PLC (0001625297) (Subject)

      11/15/24 6:03:54 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Indivior PLC

      SC 13G/A - INDIVIOR PLC (0001625297) (Subject)

      11/14/24 5:00:25 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Indivior PLC

      SC 13D/A - INDIVIOR PLC (0001625297) (Subject)

      11/7/24 8:23:16 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDV
    Leadership Updates

    Live Leadership Updates

    See more
    • Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

      RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr

      7/8/25 8:00:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Appoints Tony Kingsley to the Board of Directors

      RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of

      6/24/25 4:12:00 PM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indivior Announces Patrick Barry as Chief Commercial Officer

      Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va., May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry will lead the company's commercial growth strategy, execution, and operations as Indivior continues its mission to transform the treatment of opioid use disorder led by SUBLOCADE® (buprenorphine extended-release) Injection. Barry will join Indivior's executive committee. "Patrick is an accomplished and resp

      5/27/25 8:30:00 AM ET
      $INDV
      Biotechnology: Pharmaceutical Preparations
      Health Care